We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · January 26, 2020

Capecitabine-Based Chemo-Endocrine Combination in the First-Line for Metastatic HR-Positive Metastatic Breast Cancer

Clinical Breast Cancer


Additional Info

Disclosure statements are available on the authors' profiles:

Clinical Breast Cancer
Capecitabine Based Chemo-Endocrine Combination as First Line Treatment for Metastatic Hormonal Positive Metastatic Breast Cancer: A Phase II Study.
Clin. Breast Cancer 2020 Jan 07;[EPub Ahead of Print], N Rashad, T Abdelhamid, SA Shouman, H Nassar, MA Omran, ED El Desouky, H Khaled

Further Reading